
NxThera
Medical device to improve urinary flow of men and develops patient quality of life.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
N/A | €0.0 | round | |
investor investor investor | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
investor investor investor investor | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
$306m Valuation: $306m | Acquisition | ||
Total Funding | 000k |






Related Content
There appears to be a mix-up between two separate companies named NxThera.
The first, a UK-based company now part of Verint Systems, specializes in automated compliance and assurance technologies. This firm focuses on the financial sector, providing solutions that ensure the accurate recording and retention of complex communications like voice, data, and text. Serving top global investment banks, Nxtera's software automates the monitoring and testing of communication and recording services to meet evolving regulatory requirements. Its product suite, which includes Proof, Parity, Reflect, Retrieve, and Verify, offers compliance assurance, testing, and operational intelligence. The business model centers on alleviating compliance stress for financial institutions by delivering real-time operational confirmation and regulatory evidence, thus preventing costly fines and reputational damage. The company generates revenue by selling its software solutions and forming channel partnerships.
The second, a US-based medical device company from Maple Grove, Minnesota, was founded in 2008 by Michael Hoey. This NxThera pioneered the use of convective water vapor energy to treat urological conditions, most notably benign prostatic hyperplasia (BPH). The founder's journey was deeply personal, driven by his father's battle with prostate cancer and the severe side effects of traditional treatments. A significant milestone was achieved in 2015 when its Rezūm™ System received FDA clearance. This system uses radiofrequency energy to convert water into vapor, which is then used to ablate obstructive prostate tissue in a minimally invasive procedure. The company successfully raised approximately $148 million in funding over 12 rounds from investors including Aberdare Ventures and Arboretum Ventures. In March 2018, Boston Scientific acquired this NxThera for an upfront payment of $306 million, with potential for an additional $100 million in milestones. As part of the acquisition, the technology's application for treating cancer was spun off into a new entity.
Keywords: regulatory compliance, communication recording, compliance assurance, financial services technology, automated testing, operational intelligence, trade surveillance, Verint, compliance monitoring, risk management, medtech, urology, benign prostatic hyperplasia, BPH, water vapor therapy, Rezūm System, Michael Hoey, Boston Scientific, medical devices, minimally invasive surgery, prostate treatment, endourology, convective energy